Her2 Negative Metastatic Breast Cancer Therapeutics
1. Halaven patent expiration
Treatment: Treatment of patients with metastatic breast cancer
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8097648 | EISAI INC | Methods and compositions for use in treating cancer |
Jan, 2021
(4 years ago) | |
| US6469182 | EISAI INC | Intermediates in the preparation of macrocyclic analogs |
Jun, 2019
(6 years ago) | |
| US7470720 | EISAI INC | Methods and compositions for use in treating cancer |
Jun, 2019
(6 years ago) | |
| US6214865 | EISAI INC | Macrocyclic analogs and methods of their use and preparation |
Jun, 2019
(6 years ago) | |
|
US6214865 (Pediatric) | EISAI INC | Macrocyclic analogs and methods of their use and preparation |
Jan, 2024
(1 year, 11 months ago) | |
| USRE46965 | EISAI INC | Intermediates for the preparation of analogs of Halichondrin B |
Jan, 2027
(11 months from now) | |
|
USRE46965 (Pediatric) | EISAI INC | Intermediates for the preparation of analogs of Halichondrin B |
Jul, 2027
(1 year, 5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 15, 2015 |
| New Indication(I-721) | Jan 28, 2019 |
| Orphan Drug Exclusivity(ODE) | Jan 28, 2023 |
| Orphan Drug Exclusivity(ODE-107) | Jan 28, 2023 |
| M(M-280) | Sep 13, 2025 |
| Pediatric Exclusivity(PED) | Mar 13, 2026 |
Drugs and Companies using ERIBULIN MESYLATE ingredient
NCE-1 date: 13 March, 2025
Market Authorisation Date: 15 November, 2010
Dosage: SOLUTION
How can I launch a generic of HALAVEN before it's drug patent expiration?
More Information on Dosage
HALAVEN family patents
